RT Journal Article
T1 Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers
A1 Gómez Ballesteros, Miguel
A1 Andrés Guerrero, Vanesa
A1 Parra Luna, Francisco
A1 Marinich, Jorge
A1 Heras Polo, Beatriz De Las
A1 Molina Martínez, Irene Teresa
A1 Vázquez Lasa, Blanca
A1 San Román Del Barrio, Julio
A1 Herrero Vanrell, María Del Rocío
AB Topical application of drops containing ocular drugs is the preferred non-invasive route to treat diseases that a_ect the anterior segment of the eye. However, the formulation of eye drops is a major challenge for pharmacists since the access of drugs to ocular tissues is restricted by several barriers. Acetazolamide (ACZ) is a carbonic anhydrase inhibitor used orally for the treatment of ocular hypertension in glaucoma. However, large ACZ doses are needed which results in systemic side e_ects. Recently, we synthesized copolymers based on 2-hydroxyethyl methacrylate (HEMA) and a functionalized three-arm poloxamer star (Bayfit-MA). The new material (HEMA/Bayfit-MA) was engineered to be transformed into nanoparticles without the use of surfactants, which represents a significant step forward in developing new ophthalmic drug delivery platforms. Acetazolamide-loaded nanocarriers (ACZ-NPs) were prepared via dialysis (224 +/- 19 nm,  ̶ 17.2 +/- 0.4 mV). The in vitro release rate of ACZ was constant over 24 h (cumulative delivery of ACZ: 83.3 +/- 8.4%). Following standard specifications, ACZ-NPs were not cytotoxic in vitro in cornea, conjunctiva, and macrophages. In normotensive rabbits, ACZ-NPs generated a significant intraocular pressure reduction compared to a conventional solution of ACZ (16.4% versus 9.6%) with the same dose of the hypotensive drug (20 μg). In comparison to previously reported studies, this formulation reduced intraocular pressure with a lower dose of ACZ. In summary, HEMA:Bayfit-MA nanoparticles may be a promising system for ocular topical treatments, showing an enhanced ocular bioavailability of ACZ after a single instillation on the ocular surface.
PB MDPI
SN 2073-4360
YR 2019
FD 2019-07-19
LK https://hdl.handle.net/20.500.14352/12759
UL https://hdl.handle.net/20.500.14352/12759
LA eng
NO Gómez Ballesteros, M., Andrés Guerrero, V., Parra Luna, F. et al. «Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers». Polymers, vol. 11, n.o 7, julio de 2019, p. 1213. DOI.org (Crossref), https://doi.org/10.3390/polym11071213.
NO Gómez Ballesteros, M., Andrés Guerrero, V., Parra Luna, F. et al. «Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers». Polymers, vol. 11, n.o 7, julio de 2019, p. 1213. DOI.org (Crossref), https://doi.org/10.3390/polym11071213.
NO Ministerio de Economía, Comercio y Empresa (España)/Fondo Europeo de Desarrollo Regional
NO Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 6 abr 2025